These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 15261177)
1. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. Rusconi P; Gómez-Marín O; Rossique-González M; Redha E; Marín JR; Lon-Young M; Wolff GS J Heart Lung Transplant; 2004 Jul; 23(7):832-8. PubMed ID: 15261177 [TBL] [Abstract][Full Text] [Related]
2. Carvedilol therapy in pediatric patients with dilated cardiomyopathy. Askari H; Semizel E; Bostan OM; Cil E Turk J Pediatr; 2009; 51(1):22-7. PubMed ID: 19378887 [TBL] [Abstract][Full Text] [Related]
3. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy. Tatli E; Kurum T Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561 [TBL] [Abstract][Full Text] [Related]
4. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Bajcetic M; Kokic Nikolic A; Djukic M; Kosutic J; Mitrovic J; Mijalkovic D; Jovanovic I; Simeunovic S; Spasic MB; Samardzic R Clin Ther; 2008 Apr; 30(4):702-14. PubMed ID: 18498919 [TBL] [Abstract][Full Text] [Related]
5. Treatment of dilated cardiomyopathy with carvedilol in children. Erdoğan I; Ozer S; Karagöz T; Celiker A; Ozkutlu S; Alehan D Turk J Pediatr; 2009; 51(4):354-60. PubMed ID: 19950843 [TBL] [Abstract][Full Text] [Related]
6. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report. Gachara N; Prabhakaran S; Srinivas S; Farzana F; Krishnan U; Shah MJ Indian Heart J; 2001; 53(1):74-8. PubMed ID: 11456146 [TBL] [Abstract][Full Text] [Related]
9. [The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy]. Metra M; Nodari S; Garbellini M; Boldi E; Rosselli F; Milan E; Giubbini R; Dei Cas L Cardiologia; 1997 May; 42(5):503-12. PubMed ID: 9289367 [TBL] [Abstract][Full Text] [Related]
10. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. Metra M; Nardi M; Giubbini R; Dei Cas L J Am Coll Cardiol; 1994 Dec; 24(7):1678-87. PubMed ID: 7963115 [TBL] [Abstract][Full Text] [Related]
11. Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Franciosa JA; Massie BM; Lukas MA; Nelson JJ; Lottes S; Abraham WT; Fowler M; Gilbert EM; Greenberg B; Am Heart J; 2004 Oct; 148(4):718-26. PubMed ID: 15459606 [TBL] [Abstract][Full Text] [Related]
13. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419 [TBL] [Abstract][Full Text] [Related]
14. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Rhodes J; Margossian R; Darras BT; Colan SD; Jenkins KJ; Geva T; Powell AJ Pediatr Cardiol; 2008 Mar; 29(2):343-51. PubMed ID: 17885779 [TBL] [Abstract][Full Text] [Related]
16. Modulation of neurohormonal activity after treatment of children in heart failure with carvedilol. Giardini A; Formigari R; Bronzetti G; Prandstraller D; Donti A; Bonvicini M; Picchio FM Cardiol Young; 2003 Aug; 13(4):333-6. PubMed ID: 14694952 [TBL] [Abstract][Full Text] [Related]
17. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Kurum T; Tatli E; Yuksel M Tex Heart Inst J; 2007; 34(1):52-9. PubMed ID: 17420794 [TBL] [Abstract][Full Text] [Related]
18. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure. Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269 [TBL] [Abstract][Full Text] [Related]
19. Clinical and echocardiographic outcome in patients receiving carvedilol for treatment of dilated cardiomyopathy. Saxena A; Anil OM; Juneja R Indian J Pediatr; 2013 Jul; 80(7):549-54. PubMed ID: 23412984 [TBL] [Abstract][Full Text] [Related]
20. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]